Sannabis announces supplier agreement with Colombian grower

Sannabis has entered into a supply agreement with a licensed Colombian cannabis cultivator to provide Sannabis-branded cannabis flower for distribution through the Sannabis Human Fine IPS Health Clinics and the Sannabis Human Fine Pharmacy-expected to be among the first authorized dispensaries in Colombia.

Under this new agreement, Sannabis will receive a consistent supply of high-quality, compliant cannabis flower cultivated specifically for medical use. The product will be used in the Human Fine's clinics, in partnership with Sannabis, for patient prescriptions and distributed through its pharmacy in accordance with upcoming national regulations.

To support the safe, effective, and compliant rollout of medical cannabis flower nationwide, Sannabis' medical team will begin hosting professional workshops for physicians, providing training on how to prescribe cannabis flower responsibly: Matching cannabinoid profiles to individual patient needs; Safe integration of cannabis oil and flower into treatment plans; and Standard-of-care protocols for chronic pain, anxiety, sleep disorders, and other conditions.

Sannabis has formally submitted regulatory proposals to the Ministry of Justice outlining a structured, transparent framework for commercial cannabis distribution. This continues the Company's longstanding role in shaping Colombian cannabis regulations.

In 2015, Sannabis hosted national and regional government officials at its operations on an Indigenous Reservation, contributing directly to the protocols used in Colombia's first cannabis legalization decree.

"Now that Colombia is regulating cannabis flower for medical distribution, Sannabis is once again stepping up with constructive, experience-based recommendations that prioritize patient access, product safety, and transparent oversight," said Juan P. Guzman, CEO of Sannabis, Inc. and Director of Sannabis S.A.S.

Sannabis will announce its commercial distribution plan once the Ministry finalizes regulations and approves the Sannabis proposed protocols. Initial plans include expanding pharmacy operations, scaling supply capacity, and establishing distribution routes through health-sector partners.